Genitourinary Cancers | Specialty

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

June 24th 2011

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Dr. Cella on His Focus in the Axitinib and Sorafenib Trial

June 21st 2011

Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial

Dr. Cella Discusses Axitinib and Sorafenib Axis Trial

June 17th 2011

Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial

Prolonged Use of Diabetes Drug Actos May Increase Risk of Bladder Cancer

June 16th 2011

The FDA announced that the prolonged use of pioglitazone (Actos) for more than 1 year has been linked to an increased risk of bladder cancer

Axitinib Outperforms Sorafenib in Renal Cell Carcinoma Trial

June 7th 2011

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

Myths and Facts About Kidney Cancer

April 12th 2011

March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.

March Net Guide: Kidney Cancer

April 5th 2011

Kidney cancer resource from across the web including blogs, associations, journals, clinical trials and online CME offerings

Federal Spending on Research Into Kidney Cancer Is Rising

April 4th 2011

The use of microRNAs and proteomics-based approaches for early detection are among the foremost research priorities of the National Cancer Institute

Resources for People Living with Kidney Cancer

April 4th 2011

Help kidney cancer patients by being aware of available resources and support services

Dr. Alter on Trials and Ongoing Research in Kidney Cancer

March 21st 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Dr. Molina on Information for the Public on Kidney Cancer

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.

Dr. Alter on Kidney Injury in Relation to Patient Recovery

March 14th 2011

Dr. Robert Alter on ASCO GU-Kidney Cancer Findings

March 14th 2011

Dr. Alter Discusses Research at JTCC

March 14th 2011

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Dr. Alter on Kidney Cancer Drugs From 2005-2010

March 14th 2011

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.

Advances in Kidney Cancer Over the Past Several Years

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years

Advice for Newly Diagnosed Kidney Cancer Patients

March 14th 2011

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Gives Advice for Newly Diagnosed Kidney Cancer Patients

Pazopanib, Sunitinib and Other Recent Clinical Trials

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Talks About Pazopanib, Sunitinib and Other Recent Clinical Trials

Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating Agents

March 4th 2011

Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase

A Review of Data on Optimal Sequencing and Combinations of Current Therapies in Renal Cell

March 4th 2011

The past 2 to 3 decades saw a palpable therapeutic nihilism associated with the management of patients with advanced renal cell carcinoma (RCC), interrupted briefly by the initial excitement regarding high-dose interleukin-2.